Managing Toxicities of TKIs and HIF-2 inhibitor in Renal Cell Carcinoma (RCC)

Welcome back to the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by world-renowned medical oncologist Dr. Monty Pal from the City of Hope. Together, they dived deep into the management of side effects associated with tyrosine kinase inhibitors (TKIs) and HIF-2 alpha inhibitors used in treating renal cell carcinoma (RCC).Episode Highlights:• Understanding TKIs and HIF-2 Inhibitors: A discussion on the available oral treatment options for RCC, including cabozantinib, lenvatinib, and axitinib.• Dosing Strategies: Insights on starting doses, titration, and the importance of managing side effects without compromising quality of life.• Common Side Effects: hypertension, diarrhea, fatigue, and how they relate to the class effect of these medications.• Clinical Pearls: Dr. Pal shared valuable tips on managing toxicities, including the use of treatment breaks and supportive care strategies.• Second-Line Treatments: A look at tivozanib and belzutifan, including their unique side effects and management strategies.Join us as we emphasized the importance of maintaining quality of life for patients undergoing treatment for metastatic RCC. Follow us on social media:•⁠ ⁠X/Twitter: https://twitter.com/oncbrothers•⁠ ⁠Instagram: https://www.instagram.com/oncbrothers•⁠ Website: https://oncbrothers.com/Don't forget to check out our other episodes for more insights on treatment algorithms, conference highlights, and challenging cases from the community.